Increased cortical atrophy in patients with Alzheimer’s disease and type 2 diabetes mellitus

Background: The risk of Alzheimer’s disease (AD) is increased in type 2 diabetes (DM2). This increased risk has been attributed to vascular comorbidity, but other mechanisms, such as accelerated ageing of the brain, have also been implicated. Objective: To determine whether AD in patients with DM2 is associated with an increased occurrence of vascular lesions in the brain, by increased cerebral atrophy, or a combination of both. Methods: In total, 29 patients with AD and DM2 and 58 patients with AD and without DM2 were included in the study. Clinical characteristics were recorded, and a neuropsychological examination and magnetic resonance imaging (MRI) scan were performed. MRI scans were rated for cortical and subcortical atrophy, medial temporal lobe atrophy, white matter lesions, and infarcts. Results: The neuropsychological profiles of the two groups were identical. Patients with AD and DM2 had increased cortical atrophy on MRI (p<0.05) compared with the non-DM2 group. In addition, infarcts were more common (odds ratio 2.4; 95% CI 0.8 to 7.8), but this effect did not account for the increased atrophy. The other MR measures did not differ between the groups. Conclusion: The results suggest that non-vascular mechanisms, leading to increased cortical atrophy, are also involved in the increased risk of AD in DM2.

[1]  P. Scheltens,et al.  Diabetes and cognitive impairment. Clinical diagnosis and brain imaging in patients attending a memory clinic. , 2006, Journal of neurology.

[2]  W. Markesbery,et al.  AD lesions and infarcts in demented and non‐demented Japanese‐American men , 2005, Annals of neurology.

[3]  J. Schneider,et al.  Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology , 2004, Neurology.

[4]  Carole Dufouil,et al.  Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. , 2004, Diabetes.

[5]  P. Scheltens,et al.  Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability , 1995, Journal of Neurology.

[6]  A. Hofman,et al.  Silent brain infarcts and the risk of dementia and cognitive decline. , 2003, The New England journal of medicine.

[7]  Matthijs Oudkerk,et al.  Incidence and Risk Factors of Silent Brain Infarcts in the Population-Based Rotterdam Scan Study , 2003, Stroke.

[8]  Clay B. Holroyd,et al.  Potential roles of insulin and IGF-1 in Alzheimer ’ s disease , 2003 .

[9]  B Schmand,et al.  Visual association test to detect early dementia of the Alzheimer type , 2002, Journal of neurology, neurosurgery, and psychiatry.

[10]  G. Biessels,et al.  Ageing and diabetes: implications for brain function. , 2002, European journal of pharmacology.

[11]  L. Launer,et al.  Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. , 2002, Diabetes.

[12]  L. Frölich,et al.  A Disturbance in the Neuronal Insulin Receptor Signal Transduction in Sporadic Alzheimer's Disease , 1999, Annals of the New York Academy of Sciences.

[13]  A. Ott Risk of dementia: The Rotterdam Study , 1997 .

[14]  F Barkhof,et al.  Qualitative Assessment of Cerebral Atrophy on MRI: Inter- and Intra-Observer Reproducibility in Dementia and Normal Aging , 1997, European Neurology.

[15]  J. Biller,et al.  Cerebrovascular disorders in patients with diabetes mellitus. , 1996, Journal of diabetes and its complications.

[16]  G. C. Román,et al.  Vascular dementia , 1993, Neurology.

[17]  P. Scheltens,et al.  A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging , 1993, Journal of the Neurological Sciences.

[18]  J. Lindeboom,et al.  De validiteit van de Amsterdamse Dementie-screeningstest , 1989 .